Non-alcoholic fatty liver disease (NAFLD) is considered the most common liver disease affecting 15-25% of the general population. 
Background
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum starting from fatty liver, fatty liver and inflammation to evidence of damage to hepatocytes and can progress to cirrhosis or in the most extreme form of NAFLD can progress to hepatocellular carcinoma or liver failure. 1 Non-alcoholic fatty liver disease is considered the most common liver disease affecting 15-25% of the general population. 2 Primary NAFLD results from insulin resistance and NAFLD is considered as part of the metabolic syndrome. [3] [4] [5] [6] Essential hypertension is considered an insulin resistant state 7, 8 and through the basis of insulin resistance mechanisms, recent studies consider NAFLD as an early mediator of atherosclerosis 9, 10 and an increased cardiovascular risk factor. 11 The aim of the present study was to investigate the prevalence of NAFLD in grade III high and very high
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Luminita Latea, Stefania Negrea, Sorana Bolboaca "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania cardiovascular additional risk hypertensive patients according to circadian BP rhythm and to investigate the relationship between insulin sensitivity and NAFLD in essential hypertensive patients according to the circadian BP rhythm. Patients with mild or moderate essential hypertension or suspected secondary hypertension were excluded. Also patients with chronic alcoholism, diabetic mellitus, evidence of cardiovascular, pulmonary, renal, hepatic disease, and patients with previous drug-induced fatty liver treatment (corticoids, chronic salicylates, tricyclic antidepressants, tamoxifen, tetracyclines, synthetic oestrogens and amiodarone) 13, 14 were excluded from the study.
Method

Study population
Thirty-five hypertensive patients gave their informed consent before taking part in the study, completed the inclusion criteria and were therefore enrolled in the study.
All hypertensive patients underwent 24-hour ambulatory BP monitoring (ABPM) (for systolic and diastolic BP evaluation), blood tests and abdominal ultrasonography.
The ABPM was performed with ABPM-04, 99/BP411 -Medibase. Before the beginning of ABPM, BP was measured with a mercury sphygmomanometer, with the patient seated for at least 10 minutes. The arm with higher BP values at sphygmomanometer evaluation was chosen for ABPM. In order to reduce errors during the day all patients were asked to ensure that the arm was always parallel to the trunk when the cuff was inflated. Readings were obtained automatically at 15 minute intervals from 7:00 am to 22:00 pm and 30-minute intervals from 22:00 pm to 7:00 am. All the measurements were performed by the same investigator, using the same equipment, both at the beginning of the study and during the follow-up.
Hypertensive patients were divided into four groups according to the diurnal index (DI) from ABPM monitoring: dipper (D), non-dipper (ND), reverse-dipper (RD), and extreme-dipper (ED). The diurnal index = 100 X (the average of the diurnal values -the average of the night values)/the average of the diurnal values (N >10%). Dipper patients were defined as 10%≤DI<20%, non-dipper defined as 0 ≤DI<10%, extreme-dipper defined as DI≥20%, reversedipper defined as DI<0. 15 The diagnosis of fatty liver, was established using the noninvasive method of abdominal ultrasound followed by the exclusion of the secondary causes of hepatic steatosis: a history of another known liver disease, alcohol intake of 30g/day or more for males and 20g/day or more for females, a positive serology for hepatitis B or C virus or ingestion of drugs known to produce hepatic steatosis. The liver ultrasonography scanning was performed by standard criteria 16, 17 by the same investigator, in all patients in the morning , after overnight fasting, using the same equipment (ESAOTE My Lab, with a 3.5-MHz transducer). The presence of liver steatosis was graded semi-quantitatively according to a previously reported scale: 18 0 -absent, 1 -mild, 2 -moderate and 3 -severe steatosis.
In all hypertensive patients who fasted overnight for biochemical and metabolic profile, blood samples were evaluated by standardised routine laboratory techniques.
Serum triglycerides, total, and HDL cholesterol, glucose, insulin, alanine amino transferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) levels were measured, using routine automated assay methods. Reference range of values, are 0-40 IU/l for ALT, 0-37 IU/l for AST, 6-20 mIU/ml for insulinaemia, 0-50 IU/l for cGT, 70-170 mg/dl for triglycerides, 60-110 mg/dl for glucose, and up to 200 mg/dl for total cholesterol.
Insulin resistance was calculated by the homeostasis monitoring assessment (HOMA) formula. The HOMA index was calculated as the product of the fasting plasma insulin level (μU/mL) and the fasting plasma glucose level (mmol/L), divided by 22.5.
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Statistical analysis
Descriptive statistics, including means, SD, ranges and percentages, were used to characterise the study subjects. 
Results
NAFLD was present in 14 hypertensive patients (40%) with grade III essential hypertension with high and very high additional cardiovascular risk as reported in Figure 1 . No statistically significant differences were observed between the four groups of patients in terms of demographic baseline characteristics (p>0.05).
Baseline demographic, clinical and laboratory characteristics of the study population are presented in Table 1 .
The prevalence of NAFLD was significantly higher in the nondipper hypertensive patients group 54.54% (n=6), the reverse-dipper hypertensive patients group 50% (n=2) and the extreme-dipper hypertensive patients group 33.33% (n=1) compared to the dipper hypertensive patients group 29.41% (n=5)( p<0.05) as reported in Figure 2 . 
100%
The association between the non-dipper status and insulin resistance that was observed in the present study has already been demonstrated. 23 29, 30 and cerebrovascular disease. 31 The small number of the patients included was a study limitation. Additional research is needed to identify the specific ways in which insulin resistance links the NAFLD and altered BP status.
Conclusion
The altered BP status of hypertension associated both a 
Discussion
This study revealed a significant statistical difference of the NAFLD prevalence, between the altered dipping status (nondipper, reverse-dipper, and extreme-dipper) and the normal dipping status of hypertensive patients. A higher prevalence of the NAFLD was observed in non-dipper hypertensive patients, followed by reverse-dipper and extreme-dipper when compared with dipper hypertensive patients. The liver steatosis grade was more severe in the reverse-dipper group of hypertensive patients who presented moderate and severe steatosis. All extreme-dipper hypertensive patients presented a moderate grade of steatosis of disease. Grade III essential hypertensive patients with the altered dipping profile (ND, RD, ED) revealed a statistically significant higher level of plasma insulin when compared to the dipper group of hypertensive patients suggesting that insulin resistance could play a role in the tendency of a greater end organ damage in hypertensive patients with an altered BP circadian rhythm (non-dipper, reverse-dipper, extreme-dipper). 21, 22 higher insulin resistance and a higher prevalence of NAFLD. This brings us to the conclusion that insulin resistance could be the pathogenic link between the NAFLD and altered BP status. Altered BP status could be a marker of the NAFLD in hypertensive patients. 
